Young R C, Goldberg D, Grotzinger K R
Cell Tissue Kinet. 1976 Jul;9(4):325-32. doi: 10.1111/j.1365-2184.1976.tb01280.x.
Methyl CCNU produces a suppression of tritiated thymidine (3H-TdR) incorporation into DNA in vivo in normal bone marrow and gastrointestinal tissues which is different in magnitude and duration from that seen in L1210 ascites tumor in the same animals. This suppression and recovery pattern is not seen in animals bearing L1210 ascites tumor resistant to MeCCNU. Where a different pattern of recovery is seen between normal host target tissues and tumor, the pattern can be exploited to increase the cure rate of animals bearing advanced L1210 ascites tumor with properly spaced second doses of MeCCNU. Additional information on the potential toxicity of second doses of MeCCNU can be predicted from knowledge of the time of recovery of DNA synthesis in the normal host target tissues.
甲基CCNU能抑制正常骨髓和胃肠道组织中体内3H-胸腺嘧啶核苷(3H-TdR)掺入DNA的过程,其抑制程度和持续时间与同一动物体内L1210腹水瘤中的情况不同。在对甲基CCNU耐药的L1210腹水瘤动物中未观察到这种抑制和恢复模式。当正常宿主靶组织和肿瘤之间出现不同的恢复模式时,可利用该模式通过适当间隔给予第二剂甲基CCNU来提高晚期L1210腹水瘤动物的治愈率。根据正常宿主靶组织中DNA合成恢复时间的知识,可以预测第二剂甲基CCNU的潜在毒性的更多信息。